Dr. Hyeryun Choe is a leading researcher at Boston Children's Hospital specializing in viral entry mechanisms and receptor identification. She directs the Choe Laboratory, which investigates how viruses including HIV-1, SARS-CoV, and Zika virus enter host cells. Her work has significant implications for developing antiviral therapies and vaccines against emerging pathogens. Dr. Choe received her PhD from Pennsylvania State University in Cellular and Molecular Biology. Her postdoctoral training included work at Beth Israel Hospital on TFR1 receptor-mediated endocytosis and at Dana Farber Cancer Institute on HIV-1 research. She has established her independent laboratory at Boston Children's Hospital, spent time at The Scripps Research Institute's Florida Campus, and returned to Boston Children's Hospital in 2023. Dr. Choe's research primarily focuses on viral entry mechanisms, with particular emphasis on identifying cellular receptors for clinically important viruses. Her laboratory has made seminal contributions to understanding how HIV-1 uses CCR5 and other coreceptors, how SARS-CoV utilizes ACE2 as its receptor, and how New World hemorrhagic fever arenaviruses employ TFR1. She discovered that tyrosine sulfation is the sole common feature of all known HIV-1 coreceptors and is essential for their function. Her work also revealed that lysosomal enzymes cathepsins B and L are essential for SARS-CoV entry, TIM1 is a general entry-enhancing host factor for many viruses, and AXL mediates Zika virus infection of fetal endothelial cells, potentially contributing to fetal microcephaly. Analysis of Dr. Choe's recent publications reveals a consistent focus on coronavirus research, particularly SARS-CoV-2. Her work spans viral entry mechanisms, vaccine development, and antiviral therapeutics. She has made significant contributions to understanding how the virus enters cells, how it adapts to humans, and how to develop effective countermeasures including engineered ACE2 proteins and improved vaccine platforms. Her research also extends to HIV-1 and Zika virus, demonstrating breadth across multiple viral pathogens while maintaining a unifying theme of viral entry mechanisms. Dr. Choe has made substantial contributions to the field of virology through her laboratory's discoveries. While specific awards aren't listed in the provided information, her high-impact publications in top journals like Nature, Science, and Cell demonstrate recognition of her work by the scientific community. As principal investigator of the Choe Laboratory, Dr. Choe oversees research projects spanning multiple areas of viral pathogenesis. Her team investigates viral entry mechanisms across different virus families, develops novel antiviral strategies including AAV vectors for targeted delivery, and works on improving protein therapeutics for viral diseases. Current projects include developing AAV vectors that specifically target CD4+ T cells or B cells, engineering B cells for HIV-1 vaccine evaluation, and finding strategies to minimize antibody-dependent enhancement in dengue virus infection. The Choe Laboratory operates at the intersection of virology, cell biology, and structural biology, employing biochemical, cell biological, and structural approaches to understand viral entry mechanisms. The lab collaborates with other research groups, including the Farzan lab, to develop innovative antiviral strategies. Current work focuses on applying insights from viral entry research to develop improved vaccine platforms and therapeutic interventions for multiple viral pathogens.
جستوجوی استاد و پژوهشگر
استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشیتان را پیدا کنید و با او ارتباط بگیرید.
نمایش ۴۸۱-۴۸۳ از ۴۸۳ استاد راهنما
اطلاعات این پروفایلها از صفحات عمومی دانشگاهها جمعآوری شده و ممکن است بهروز نباشد.
Seongkyu Yoon is a Professor of Chemical Engineering at the Francis College of Engineering, University of Massachusetts Lowell. He serves as co-Director of the Massachusetts Biomanufacturing Center, UMass Site Director of the NSF/IUCRC Research Center (AMBIC - Advanced Mammalian Bioprocessing Innovation Center), and UMass technical lead for Manufacturing USA in Biomanufacturing (NIIMBL). His academic appointments and leadership roles position him at the forefront of biopharmaceutical manufacturing innovation and workforce development. Dr. Yoon's educational background demonstrates his interdisciplinary expertise: Ph.D. in Chemical Engineering (2001), McMaster University - Hamilton, Canada MBA (2017), Babson College - Wellesley, MA M.S. in Chemical and Biomolecular Engineering (1990), Korea Advanced Institute of Science and Technology - Daejon, Korea B.S. in Chemical Engineering (1988), Yonsei University - Seoul, Korea His research program focuses on systems engineering approaches to life sciences with three primary thrusts: Gene and Cell Therapy, Biomanufacturing Innovation, and Formulation and Drug Delivery. Within Gene and Cell Therapy, his group explores alternative hosts for Adeno-associated Virus production, gene therapy media optimization, CRISPR-CAS9 mediated genome engineering of HEK293 cells, and develops analytical methods for quantification of full, partial, and empty capsids in AAV products. His Biomanufacturing Innovation research includes AI-enabled hyperspectral imaging for cell culture monitoring, metabolic flux analysis of iPS cells, integrated MPC systems for bioprocess engineering, and digital-twin model development. In Formulation and Drug Delivery, his team works on single vial mass flow rate monitoring for pharmaceutical freeze-drying heterogeneity. Analysis of Dr. Yoon's recent publications reveals a strong trend toward advanced biomanufacturing technologies, particularly in viral vector production for gene therapy. His work integrates systems biology, metabolic modeling, and process analytics to address critical challenges in biopharmaceutical manufacturing. A significant portion of his research focuses on CHO cell culture optimization, glycosylation control, and continuous bioprocessing technologies, reflecting industry needs for more efficient and robust manufacturing platforms. Among his notable recognitions: Ward Chaired Professor of Biomedical Material Sciences (2016) NSF/IUCRC: AMBIC, Advanced Mammalian Bioprocessing Innovation Center (2016) Control and estimation of glycosylation profile via media supplementation based on intracellular models in mammalian cell cultures (2017) Data-fusion based platform development of population PKPD modeling and statistical analysis for bioequivalenc (2015) Dr. Yoon has mentored numerous graduate students, with many now working at major pharmaceutical and biotechnology companies including AbbVie, Alexion, BMS, Amgen, Takeda, and Genentech. His research group has received substantial funding from NSF, FDA, and industry partners, supporting an integrated approach to biomanufacturing innovation. He has also developed and led numerous professional training programs in bioprocessing, contributing significantly to workforce development in the biopharmaceutical industry. His research group operates within the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) and collaborates closely with the Biomanufacturing Innovation Institute. The team includes postdoctoral researchers, graduate students, and research staff working on various aspects of bioprocess engineering, systems biology, and biomanufacturing analytics. They maintain strong industry partnerships that ensure their research addresses real-world challenges in biopharmaceutical manufacturing.
Maurizio V. Cattaneoمشاهده پروفایل
استاد پژوهشی
Maurizio V. Cattaneo is a Research Professor in the Chemical Engineering Department at the Francis College of Engineering, University of Massachusetts Lowell, where he advances bioprocess engineering with emphasis on viral vector manufacturing and gene therapy delivery systems through Quality by Design and Process Analytical Technologies. His academic foundation includes: Ph.D. in Chemical Engineering, McGill University M.Eng. in Chemical Engineering, McGill University B.S., University of Toronto Dr. Cattaneo pioneers viral and non-viral delivery systems (AAV, LV, RV, LNPs) for gene therapy and develops patented AI-driven hyperspectral imaging for real-time bioprocess monitoring. His patented Viral Harvest Unit (VHU) revolutionizes viral vector perfusion in bioreactors, significantly enhancing manufacturing efficiency and scalability. His 2018-2023 publications reveal a decisive shift toward continuous bioprocessing for viral vector production, integrating perfusion technologies with AI analytics. This multidisciplinary work spans influenza virus particles, retroviral vectors, and metabolite quantification systems, demonstrating convergence of biotechnology, chemical engineering, and artificial intelligence to solve critical manufacturing bottlenecks. Key scientific recognitions include: 1978 Ontario Scholar 1980 NSERC Research Grant 1997 NRC Canada Government Priority Funds As Principal Investigator, he secured multiple NIH SBIR grants (2000-2004) from the National Cancer Institute, National Institute of Aging, and National Center for Complementary Medicine for drug delivery systems targeting cancer chemoprevention, wound healing, and osteoarthritis. His entrepreneurial impact spans founding IVREA Pharmaceuticals, BioVolutions, and Artemis Biosystems. Current research focuses on CELiD DNA for non-viral Type I Diabetes gene therapy and advanced encapsulation technologies for biologics delivery, positioning him at the forefront of next-generation therapeutic manufacturing.